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S268 Poster Session Idays. While race/ethnicity (p\0.0001) and disease (p 5 0.01) were
associated with finding a donor, other variables (age, gender,
CIBMTR risk, CMV, KPS, socio-economic status) were not.
Among those with a donor, logistic regression modeling identified
increasing age (p 5 0.02), non-Caucasian race/ethnicity (p 5
0.002), and high CIBMTR risk (p 5 0.007) as associated with de-
creased odds for reaching HCT. Among 448 patients in the donor
group, 239 underwent HCT. Of those in the no donor group, a total
of 14 underwent double umbilical cord blood transplant (dUCBT).
In the primary ITT analysis, we studied outcome according to
donor vs. no donor status from time of search initiation using
a time-dependent Cox model. Compared to no donor, donor status
had reduced hazard for mortality (HR of 0.85, 95% CI 0.63 -1.2,
p 5 0.3). Accounting for interaction, those with KPS 90-100 and
donor had significantly reduced hazard (HR 0.59, 95% CI 0.38 -
0.90, p 5 0.02) compared to no donor. Secondary analyses exam-
ined outcome by treatment received: Those who received the
intended HCT in the donor group had significantly reduced hazard
(HR 0.64, 95%CI 0.46 – 0.89, p5 0.009) compared to no donor. In
a separate analysis, donor, dUCBT, and no donor/no UCBT were
treated as time-varying covariates, demonstrating significantly re-
duced hazard for donor vs. no donor (HR 0.57, 95% CI 0.43-
0.76, p 5 0.0001). No significant effect of matching (7/8 vs. 8/8)
was detected in any analyses. In total, these data provide new insight
into factors associated with unrelated donor identification according
to high-resolution typing methods, identify factors relevant to
reaching HCT among those with a suitable donor, and speak to
the efficacy of unrelated donor HCT.175
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Unrelated cord blood transplantation (CBT) is not widely used
to treat hemoglobinopathies (HGB) despite being the fastest grow-
ing stem cell source for unrelated hematopoietic cell transplanta-
tion (HCT). Published series show unfavorable disease-free
survival (Ruggeri et al. BBMT 2011) or were single institution
efforts (Jaing et al. BMT 2011). We analyzed the clinical outcome
for 101 HGB patients following CBT. The combination approach
to optimize nucleated cell (NC) dose of choosing CB products
manufactured by plasma depletion/reduction to maximize NC re-
covery, double grafts (whenever single CB had insufficient NC
dose), and post-thaw direct infusion were used by the 5 Asian
transplant centers (TCs) in this series that performed most of the
CBT. A CIBMTR on site-audited analysis was performed on 91
thalassemia and 10 sickle cell disease (SCD) patients transplanted
between 1999 and 2011 at 25 TCs in 6 countries using 114 CB
products processed by plasma depletion/reduction (88%) and 15
CB units processed by red cell reduction. 84% of the CB were in-
fused directly without post-thaw wash/reconstitution and 19% of
the transplants employed double CB grafts. Most TCs reported us-
age of no-TBI preparative regimens or ones that included Bu/Cy/
ATG. Graft failure rate at some TCs declined after switching from
oral busulfan to IV formulations, and 7 patients received a second
CBT. 24% of the transplants (24 patients/25 CB) were performed
at 18 U.S. TCs with the remainder (77 patients/104 CB) at 7 inter-
national TCs. 75% of the patients were Asian. Median follow-up
time was 711 days (range 2-2,877 days). Transplant characteristics:
median age 5.6 years (range 0.3-20); median patient weight 18.8 kg
(range 4-80); male 45%; HLA matches (intermediate resolution
HLA-A and -B and high resolution HLA-DRB1) of the CB used
in these patients: 6/6-23; 5/6-45; 4/6-54; 3/6-3; median pre-freezeTNC dose 9.4 x107/kg; median pre-freeze CD34+ dose 3.2 x105/
kg. The median times to myeloid and platelet engraftment were
17 days and 47 days, respectively. Of the 101 patients, 21 expired
before 180 days (20.8%); 26 prior to 1 year (25.7%) and 27 total
deaths (26.7%). To our knowledge, the current multi-center study
with 101 patients is the largest unrelated CBT series for HGB or
thalassemia. The data appear to support the notion that in the set-
ting of optimal cell dose, favorable overall and disease-free survival
may be achieved for unrelated CBT of HGB/thalassemia.
Table. Summary of Patient, CB and Transplant Characteris-
tics
Thalassemia ThalassemiaPatient
CharacteristicsAll Patients
(n 5 101)PDR CB
(n 5 79)RCR CB
(n 5 12)SCD PDR
CB (n 5 9) CSCD RCR
B (n 5 1)Age yo,
Median (Range)
5.6 (0.3-20) 5.3 (0.3-20) 4.0 (0.8-12) 12.4 (4-20) NAWeight Kg, Median
(Range)
18.8 (4-80) 18.5 (8-45) 15.1 (4-36) 34.0 (17-80) NAMale Sex % 46 43 58 44 NAAsian/Caucasian/
AFA/NA %
75/9/8/9 71/4/0/4 4/5/0/3 0/0/8/1 0/0/0/1CB Graft
Characteristics
A
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n 5 129)
T
Phalassemia
DR CB
(n 5 105)
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R
(halassemia
CR CB
n 5 13)
S
CCD PDR
B (n 5 9) CSCD RCR
B (n 5 2)HLA Match
NA,3/6,4/6,
5/6,6/6
4,3,54,45,23 1,3,42,38,21 1,0,8,3,1 0,0,4,4,1 2,0,0,0,0Pre Freeze
TNC dose,
Median (Range)
9.4 (2.3-23.7) 9.8 (2.5-23.7) 8.7 (2.3-18.6) 4.4 (2.6-10) NAPre Freeze CD34+
dose, Median
(Range)
3.2 (0.4-13.5) 3.6 (0.4-10.3) 1.5 (0.4-13.5) 1.8 (0.8-3.1) NA% CB bedside thaw 84 89 77 56 0% Double CBT 19 20 8 0 100PDR 5 Plasma Depleted/Reduced; RCR 5 Red Cell Reduced; CB 5
Cord Blood; yo5 years old; Asian5 Asian/Asian Pacific Islander/Indian;
Caucasian 5 Causian/Middle Eastern; AFA 5 African American; NA 5
Not Availlable; TNC 5 Total Nucleated Cells in 107; CD34+ cells in
10^5; beside thaw 5 direct infusion without post-thaw wash or
reconstitution176
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Aim: To investigate the impact of HLA-DPA1 and -DPB1 mis-
match on clinical outcomes in a modern era of unrelated hematopoi-
etic stem cell transplantation (HSCT).
Methods: Retrospectively, 380 consecutive patients (median age
39, range 0.5-67 years) who underwent HSCT using HLA -A,
-B, and -DRB1 allele level-matched unrelated donors at our centre
during 1995-2010, were included in the study. Most patients un-
derwent HSCT in the treatment for hematological malignancies
(81%), whereas 7% and 12% of all patients were transplanted in
the treatment for non-hematological malignancies and non-malig-
nant disorders, respectively. HLA typing using PCR-SSP (Olerup-
SSP) or PCR-SSO on a Luminex platform (One Lambda) was
performed and revealed 55 HLA-DP (A1 and B1) matched and
325 mismatched donor pairs. HLA-DPA1 and HLA-DPB1 mis-
match was noted in 35% and 85% of all recipient donor pairs, re-
spectively.
Poster Session I S269Results:HLA-DP (A1 or B1) mismatch compared to DP match did
not affect the incidences of acute graft-versus-host disease (GVHD)
grades II-IV (33% vs. 27%; P5 0.20), or grades III-IV (6% vs. 8%; P
5 0.87). Furthermore, the incidence of chronic GVHD was similar
(28% vs. 27%; P5 0.49), and there was no impact on patient overall
survival using DP mismatched compared to DP matched donors
(55% vs. 50%, P 5 0.72). However, in separate analysis DPA1 mis-
match was associated with decreased overall survival (HR 1.50, P 5
0.02), when compared to matched recipients irrespective of
HLA-DPB1 and HLA-C match. In univariate analysis, HLA-
DPA1 mismatch was associated with increased risk of transplant-
related mortality (P 5 0.04), although incidences of acute and
chronic GVHD were similar. Furthermore, a tendency to an in-
creased risk of infection-related mortality was noted in patients
mismatched for HLA-DPA1 (P 5 0.07).
Conclusions: This study suggests that HLA-DPA1 mismatch is
associated with inferior survival, which may be caused by an in-
creased risk of infection-related mortality. At present there are
few publications available, which investigate the role of DPA1
and DPB1 mismatch separately, and future studies to uncover
the importance of DPA1 and DPB1 compatibility in unrelated
HSCT are warranted.177
ETHNICITY BETWEEN DONOR AND RECIPIENT AFFECTS OVERALL
SURVIVAL IN UMBILICAL CORD BLOOD TRANSPLANTATION
Bachier, C., Cheruku, P.S., Shaughnessy, P., Chan, K., Madden, R.,
Jude, V., LeMaistre, C.F. Texas Transplant Institute, San Antonio, TX
This study retrospectively analyses the effects of ethnicity on
clinical outcomes after UCBT. Patients were transplanted at
the Texas Transplant Institute in San Antonio between 2001
and 2010. CIBMTR and hospital records supplied the data.
Two hundred and sixty patients were evaluated including Whites
(76), Hispanics (141), Blacks (19) and Asians (6). Black and Asians
were excluded from analysis due to small numbers. Age, cell
dose, myeloablative versus non-myeloablative conditioning regi-
mens, single (s) versus double (d) UCBT and the prevalence of
high risk malignancies were similar between the two ethnicities
(Table). More Whites (88%) were transplanted for malignant
diseases than Hispanics (68%) (p\0.001). Incidence of acute
and chronic graft-versus-host disease (GVHD) (Table), overall
survival (OS) (Table), disease related mortality (DRM) and
non-disease related mortality (NDRM) were similar between
Whites (DRM: 20% and NDRM: 23%) and Hispanics (DRM:
16% and NDRM: 24%) and regardless of whether they had ma-
lignant or non-malignant disease, standard or high risk malignant
disease, single or double transplants, and age. Hispanics who re-
ceived an ethnically matched s UCB product had a longer OS
(88.7 months) than Whites (68.5 months) (p 5 0.030) and
a shorter OS (43.3 months) than Whites when each received an
ethnically mismatched s UCB product (p 5 0.004). White and
Hispanics with ethnically matched and mismatched sUCBT
had similar number of patients with malignant and high risk
malignant disease.
Improvement in OS in Hispanics patients with ethnically
matched s UCB products was related to an increase in OS from
transplant related mortalities while worse OS in Hispanics with
ethnically mismatched s UCB products was related to decreases
in OS from both transplant-related and disease-related mortalities.
Cell dose and degree of HLA matching was similar for all patients
and for Whites and Hispanics with ethnically matched and mis-
matched s UCB. There was a trend to shorter OS among all pa-
tients with ethnically matched (82.3 months) versus mismatched
(68.5 months) s UCB. OS was shorter among all Hispanics with
mismatched (43.3 months) than matched (88.7 months) s UCBT
(p 5 0.001).
In conclusion, ethnicmismatches between donor and recipient ap-
pear to affect survival in s UCBT. The effect of ethnic mismatches
was more pronounced in Hispanics than Whites.Table.
Characteristics and Outcomes White HispanicNumber of patients 76 141Median age at transplant, years
(range)9.0 (0.1-79.2) 8.0 (0.1-61.7)Age category<18 61 (82%) 116 (82%)$18 13 (17%) 21 (15%)Median weight, kg (range) 25 (4-111) 26.3 (4-160)Recipient sexmale 43 (57%) 90 (65%)female 31 (41%) 50 (35%)Transplant typesingle 57 (75%) 107 (76%)double 18 (24%) 34 (24%)Recipient CMV statuspostitive 24 (32%) 61 (43%)negative 27 (36%) 41 (29%)*Malignant disease 66(88%) 96 (68%)Ethnicity match for s UCBconcordant 39 (70%) 57 (53%)discordant 10 (18%) 28 (26%)*HLA-matching, single transplants6(6) 14 (25%) 9 (8%)5(6) 28 (56%) 50 (47%)4(6) 13 (23%) 44 (41%)Median cell dosex107 TNC/kg (range) 5.7 (1.5-28.5) 5.6 (1.5-45.5)Median days ANC >500 21 (10-50) 20 (10-100)Median days platelets >20K 51 (24-165) 47 (21-167)Median days platelets >50K 60 (29-137) 49 (24-224)Grade of acute GVHDgrades II - IV 33 (44%) 48 (34%)grades III - IV 11 (15%) 31 (22%)Chronic GVHDlimited 9% 28%extensive 11% 15%Overall survival (months) 70.2 73.7Median follow-up in months (range) 28 (.25-121) 25 (.25-69)*p-value <0.05
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GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER DOUBLE-UNIT CORD
BLOOD TRANSPLANTATION (DCBT) IS ASSOCIATEDWITH UNIQUE CLIN-
ICAL FEATURES INCLUDING A HIGHER INCIDENCE OF GRADE III-IV
ACUTE GVHD (AGVHD) IN CHILDREN
Ponce, D.M.1, Gonzales, A.M.R.1, Lubin,M.N.1, Castro-Malaspina, H.1,
Geralt, S.A.1, Goldberg, J.D.1, Jakubowski, A.A.1, Papadopoulos, E.B.1,
Perales, M.-A.1, van den Brink, M.R.M.1, Young, J.W.1,
Kernan, N.A.2, O’Reilly, R.J.2, Prockop, S.E.2, Scaradavou, A.2,
Stevens, C.E.1, Barker, J.N.1 1Memorial Sloan-Kettering Cancer Center,
NewYork,NY; 2Memorial Sloan-Kettering Cancer Center, NewYork, NY
GVHD is a serious complication and common cause of transplant-
related mortality after DCBT. However, relatively little is known
about DCBT GVHD manifestations, treatment response, and risk
factors. We evaluated 108 DCBT recipients (median 37 years, range
0.9-69) transplanted for high-risk hematologic malignancies with
myeloablative (n5 81) or non-myeloablative (n5 27) conditioning,
4-6/6 HLA-matched grafts, calcineurin-inhibitor/mycophenolate
mofetil, and no ATG. With a median follow-up of 28 months, the
cumulative incidences of day 180 grade II-IV and III-IV aGVHD
were 52% (95%CI:42-62) and 24% (95%CI:15-32), respectively.
The median onset was 40 days (range 14-161), and the gut was
most commonly affected (43/54, 80%). Twenty-five patients with
mainly grade II gut aGVHD were treated with budesonide alone,
26 patients with predominantly grade III-IV aGVHD received sys-
temic corticosteroids, and treatment response was achieved in over
80% by day 56 of therapy. However, 41 patients had active
GVHD after day 100 with the majority (61%) having aGVHD,
particularly of the gut. Classical chronic GVHD was uncommon.
